Boehringer Ingelheim and Re-Vana Therapeutics announce strategic collaboration to develop long-acting ophthalmic therapies

Boehringer Ingelheim and Re-Vana Therapeutics announce strategic collaboration to develop long-acting ophthalmic therapies

Up to three development programs per year leading to a potential total deal value exceeding $1…

Continue Reading